Results 21 to 30 of about 3,330,839 (370)

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

open access: yesNature Communications, 2020
Immune checkpoint inhibitors have limited efficacy in tumors with lower mutational burden and non-permissive microenvironment. Here, the authors show that combining MEK inhibition with an agonist anti-CD40 immunostimulatory antibody improves antitumor ...
Daniel Baumann   +14 more
doaj   +1 more source

Management of Intracranial Metastases in EGFR-Mutated NSCLC: A Review of Literature following an Unusual Case Report

open access: yesCase Reports in Oncological Medicine, 2021
The arrival of subsequent generations of tyrosine-kinase inhibitors (TKIs) has significantly broaden the EGFR-mutated lung cancer therapeutic landscape.
Víctor Albarrán   +7 more
doaj   +1 more source

Tumor Microenvironment [PDF]

open access: yesMedicina, 2019
Background and Objectives: The tumor microenvironment has been widely implicated in tumorigenesis because it harbors tumor cells that interact with surrounding cells through the circulatory and lymphatic systems to influence the development and progression of cancer.
Arneth, Borros   +1 more
openaire   +4 more sources

Lacrimal gland tumors in Turkey: types, frequency, and outcomes. [PDF]

open access: yes, 2018
AIM: To evaluate the clinical, radiological, and treatment features of lacrimal gland tumors. METHODS: Retrospective review of 99 eyes of 92 patients with lacrimal gland tumors diagnosed and managed in a single institution between January 1999 and March ...
Erden, Esra   +3 more
core   +2 more sources

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

open access: yes, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch   +62 more
core   +1 more source

Tumoral calcinosis [PDF]

open access: yesJournal of Inherited Metabolic Disease, 2010
Contains fulltext : 87587.pdf (Publisher’s version ) (Closed access)
Janssen, M.C.H., Sevaux, R.G.L. de
openaire   +3 more sources

Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts

open access: yesActa Neuropathologica Communications, 2019
The diagnosis and prognostication of glioblastoma (GBM) remain to be solely dependent on histopathological findings and few molecular markers, despite the clinical heterogeneity in this entity. To address this issue, we investigated the prognostic impact
Toru Umehara   +20 more
doaj   +1 more source

MR imaging for evaluation of lesions of the cranial vault: a pictorial essay [PDF]

open access: yesArquivos de Neuro-Psiquiatria, 2003
PURPOSE: A variety of diseases affect the calvaria. They may be identified clinically as palpable masses or incidentally in radiologic examinations. There are many diagnostic possibilities, including congenital, neoplastic, inflammatory and traumatic ...
Lázaro Amaral   +5 more
doaj   +1 more source

Oral haemangiomas. Series of two case reports and review of management

open access: yesJournal of Family Medicine and Primary Care, 2022
Haemangiomas are one of the most common of all human birth defects and are based on vascular tissues. These lesions are mainly identified into two groups which are named as (a) capillary and (b) cavernous haemangioma.
Sonam Gupta   +4 more
doaj   +1 more source

Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases [PDF]

open access: yes, 2017
BACKGROUND: Cytotoxic therapy for relapsed and refractory germ cell tumors or metastatic sex cord stromal tumors is rarely effective and is often accompanied by high adverse event rates.
Albany, Costantine   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy